Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment
Abstract Backgrounds Remdesivir (RDV) is an antiviral agent approved for the treatment of coronavirus disease 2019 (COVID-19); however, is not recommended for patients with renal impairment. Due to limitations associated with prospective clinical trials, real-world data on the safety and efficacy of...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | BMC Infectious Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12879-023-08859-9 |